Mazor Robotics (NASDAQ:MZOR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “

MZOR has been the topic of several other research reports. Needham & Company LLC restated a “sell” rating on shares of Mazor Robotics in a report on Thursday, August 2nd. ValuEngine lowered shares of Mazor Robotics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 10th. Wells Fargo & Co boosted their price objective on shares of Mazor Robotics from $56.00 to $62.00 and gave the stock a “market perform” rating in a report on Tuesday, May 15th. BidaskClub upgraded shares of Mazor Robotics from a “sell” rating to a “hold” rating in a report on Friday, July 6th. Finally, Cantor Fitzgerald initiated coverage on shares of Mazor Robotics in a report on Thursday, May 31st. They issued a “neutral” rating and a $57.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $61.08.

NASDAQ:MZOR opened at $48.35 on Wednesday. Mazor Robotics has a twelve month low of $41.10 and a twelve month high of $76.56.

Mazor Robotics (NASDAQ:MZOR) last posted its earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.13). The business had revenue of $13.20 million for the quarter, compared to analyst estimates of $17.02 million. Mazor Robotics had a negative net margin of 12.80% and a negative return on equity of 7.17%. The business’s revenue was down 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.05) EPS. research analysts forecast that Mazor Robotics will post -0.12 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. Advisors Asset Management Inc. acquired a new position in Mazor Robotics in the 2nd quarter worth $451,000. Global X Management Co LLC lifted its holdings in Mazor Robotics by 19.7% in the 2nd quarter. Global X Management Co LLC now owns 506,196 shares of the medical instruments supplier’s stock worth $28,099,000 after buying an additional 83,387 shares in the last quarter. Carnegie Capital Asset Management LLC lifted its holdings in Mazor Robotics by 7.8% in the 2nd quarter. Carnegie Capital Asset Management LLC now owns 20,660 shares of the medical instruments supplier’s stock worth $950,000 after buying an additional 1,500 shares in the last quarter. Jane Street Group LLC lifted its holdings in Mazor Robotics by 1,358.5% in the 2nd quarter. Jane Street Group LLC now owns 41,945 shares of the medical instruments supplier’s stock worth $2,317,000 after buying an additional 45,278 shares in the last quarter. Finally, Centaurus Financial Inc. acquired a new position in Mazor Robotics in the 2nd quarter worth $139,000. Hedge funds and other institutional investors own 26.13% of the company’s stock.

About Mazor Robotics

Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It operates in the field of computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures.

See Also: Earnings Per Share (EPS) Explained

Get a free copy of the Zacks research report on Mazor Robotics (MZOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.